Credit Suisse is increasingly cautious on Gilead

March 9, 2012

Credit Suisse said it is increasingly cautious on Gilead's risk/reward on upcoming catalysts. The firm believes the Street is focused on upcoming 7977 GT1 naive data set but believes investment in shares should be based on the totality of its HIV and HCV franchises. Shares are Neutral rated with a $48 price target.